{"id":89964,"topic":"peptides","source":"搜狐网","title":"三星生物收购PolyPeptide，打通多肽原料药赛道 - 搜狐网","url":"https://www.sohu.com/a/1052284719_121157270","url_hash":"6c4109d4fa22fb2af718834ac8e65f4c9f4d8740","author":"","summary":"<a href=\"https://news.google.com/rss/articles/CBMiVkFVX3lxTE5nT01tSl9jcDdYN0J6UXVmTm40LXFybnVsU1VBeWxGQi1DOWV3Szd4REpYa1lIemFaMld2d0RROEFPdWFxQzdyOV9xZzdBVmNXdzRBNzhR?oc=5\" target=\"_blank\">三星生物收购PolyPeptide，打通多肽原料药赛道</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">搜狐网</font>","content":"7月20日，三星生物（Samsung Biologics）7月20日宣布，拟通过现金要约收购瑞士多肽药物原料药合同开发与生产企业PolyPeptide Group AG全部已发行股份，报价为每股44.31瑞郎，交易股权价值约14.6亿瑞郎。\n三星生物表示，此次收购将推动公司从抗体和抗体偶联药物（ADC）领域进一步拓展至多肽疗法，强化多模态CDMO（合同开发与生产组织）平台。","image_url":"https://q9.itc.cn/q_70/images03/20260720/2adf18507191416b8adaa39dcb5dcbb6.jpeg","lang":"zh","published_at":"2026-07-20T07:00:00+00:00","fetched_at":"2026-09-25T01:15:11+00:00","status":"read","starred":0,"extract_state":"ok","summary_auto":"7月20日，三星生物（Samsung Biologics）7月20日宣布，拟通过现金要约收购瑞士多肽药物原料药合同开发与生产企业PolyPeptide Group AG全部已发行股份，报价为每股44.31瑞郎，交易股权价值约14.6亿瑞郎。\n三星生物表示，此次收购将推动公司从抗体和抗体偶联药物（ADC）领域进一步拓展至多肽疗法，强化多模态CDMO（合同开发与生产组织）平台。","cluster_id":null,"extract_retries":0,"extract_error":null,"contract_version":"news_item.v1","format_contract_version":"news_item_formats.v1","dedup_url":"https://www.sohu.com/a/1052284719_121157270","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"medium","confidence":0.75,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"Medium confidence: short full text extraction produced 188 characters.","operator_guidance":{"severity":"info","recommended_action":"review_short_text","next_step":"Review the short extracted text before using it as a source.","operator_label":"Short text","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"partial_text","label":"Partial text","has_full_text":true,"has_summary":true,"content_length":188,"summary_length":188,"usable_text_length":188,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":188,"summary_length":188}},"news_item":{"id":89964,"canonical_url":"https://www.sohu.com/a/1052284719_121157270","source_url":"https://www.sohu.com/a/1052284719_121157270","title":"三星生物收购PolyPeptide，打通多肽原料药赛道 - 搜狐网","source_name":"搜狐网","author":null,"published_at":"2026-07-20T07:00:00+00:00","locale":"zh","topic":"peptides","tags":[],"rss_summary":"<a href=\"https://news.google.com/rss/articles/CBMiVkFVX3lxTE5nT01tSl9jcDdYN0J6UXVmTm40LXFybnVsU1VBeWxGQi1DOWV3Szd4REpYa1lIemFaMld2d0RROEFPdWFxQzdyOV9xZzdBVmNXdzRBNzhR?oc=5\" target=\"_blank\">三星生物收购PolyPeptide，打通多肽原料药赛道</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">搜狐网</font>","full_text":"7月20日，三星生物（Samsung Biologics）7月20日宣布，拟通过现金要约收购瑞士多肽药物原料药合同开发与生产企业PolyPeptide Group AG全部已发行股份，报价为每股44.31瑞郎，交易股权价值约14.6亿瑞郎。\n三星生物表示，此次收购将推动公司从抗体和抗体偶联药物（ADC）领域进一步拓展至多肽疗法，强化多模态CDMO（合同开发与生产组织）平台。","excerpt":"7月20日，三星生物（Samsung Biologics）7月20日宣布，拟通过现金要约收购瑞士多肽药物原料药合同开发与生产企业PolyPeptide Group AG全部已发行股份，报价为每股44.31瑞郎，交易股权价值约14.6亿瑞郎。\n三星生物表示，此次收购将推动公司从抗体和抗体偶联药物（ADC）领域进一步拓展至多肽疗法，强化多模态CDMO（合同开发与生产组织）平台。","extraction":{"state":"ok","confidence":0.75,"error":null,"explanation":"Medium confidence: short full text extraction produced 188 characters.","diagnostics_url":"/api/diagnose?url=https%3A//www.sohu.com/a/1052284719_121157270","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"medium","confidence":0.75,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"Medium confidence: short full text extraction produced 188 characters.","operator_guidance":{"severity":"info","recommended_action":"review_short_text","next_step":"Review the short extracted text before using it as a source.","operator_label":"Short text","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"partial_text","label":"Partial text","has_full_text":true,"has_summary":true,"content_length":188,"summary_length":188,"usable_text_length":188,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":188,"summary_length":188}}},"display_formats":["compact","card","full","digest_section","json"]},"daily_stack_record":{"title":"三星生物收购PolyPeptide，打通多肽原料药赛道 - 搜狐网","url":"https://www.sohu.com/a/1052284719_121157270","summary":"7月20日，三星生物（Samsung Biologics）7月20日宣布，拟通过现金要约收购瑞士多肽药物原料药合同开发与生产企业PolyPeptide Group AG全部已发行股份，报价为每股44.31瑞郎，交易股权价值约14.6亿瑞郎。\n三星生物表示，此次收购将推动公司从抗体和抗体偶联药物（ADC）领域进一步拓展至多肽疗法，强化多模态CDMO（合同开发与生产组织）平台。","source":"搜狐网","date":"2026-07-20T07:00:00+00:00","content":"7月20日，三星生物（Samsung Biologics）7月20日宣布，拟通过现金要约收购瑞士多肽药物原料药合同开发与生产企业PolyPeptide Group AG全部已发行股份，报价为每股44.31瑞郎，交易股权价值约14.6亿瑞郎。\n三星生物表示，此次收购将推动公司从抗体和抗体偶联药物（ADC）领域进一步拓展至多肽疗法，强化多模态CDMO（合同开发与生产组织）平台。","confidence":0.75,"diagnostics_url":"/api/diagnose?url=https%3A//www.sohu.com/a/1052284719_121157270","quality_bucket":"medium","failure_kind":"none","retryable":false,"quality_reason":"Medium confidence: short full text extraction produced 188 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"medium","confidence":0.75,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"Medium confidence: short full text extraction produced 188 characters.","operator_guidance":{"severity":"info","recommended_action":"review_short_text","next_step":"Review the short extracted text before using it as a source.","operator_label":"Short text","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"partial_text","label":"Partial text","has_full_text":true,"has_summary":true,"content_length":188,"summary_length":188,"usable_text_length":188,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":188,"summary_length":188}},"tags":[]},"fallback_formats":["markdown","json","html"],"actions":{"read":"/item/89964","export_markdown":"/api/items/89964/export?format=markdown","export_json":"/api/items/89964/export?format=json","diagnose":"/api/diagnose?url=https%3A//www.sohu.com/a/1052284719_121157270"},"formats":{"full":{"id":89964,"title":"三星生物收购PolyPeptide，打通多肽原料药赛道 - 搜狐网","url":"https://www.sohu.com/a/1052284719_121157270","source":"搜狐网","author":null,"published_at":"2026-07-20T07:00:00+00:00","locale":"zh","topic":"peptides","tags":[],"excerpt":"7月20日，三星生物（Samsung Biologics）7月20日宣布，拟通过现金要约收购瑞士多肽药物原料药合同开发与生产企业PolyPeptide Group AG全部已发行股份，报价为每股44.31瑞郎，交易股权价值约14.6亿瑞郎。\n三星生物表示，此次收购将推动公司从抗体和抗体偶联药物（ADC）领域进一步拓展至多肽疗法，强化多模态CDMO（合同开发与生产组织）平台。","full_text":"7月20日，三星生物（Samsung Biologics）7月20日宣布，拟通过现金要约收购瑞士多肽药物原料药合同开发与生产企业PolyPeptide Group AG全部已发行股份，报价为每股44.31瑞郎，交易股权价值约14.6亿瑞郎。\n三星生物表示，此次收购将推动公司从抗体和抗体偶联药物（ADC）领域进一步拓展至多肽疗法，强化多模态CDMO（合同开发与生产组织）平台。","reading_time_min":1,"extraction":{"state":"ok","confidence":0.75,"error":null,"explanation":"Medium confidence: short full text extraction produced 188 characters.","diagnostics_url":"/api/diagnose?url=https%3A//www.sohu.com/a/1052284719_121157270","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"medium","confidence":0.75,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"Medium confidence: short full text extraction produced 188 characters.","operator_guidance":{"severity":"info","recommended_action":"review_short_text","next_step":"Review the short extracted text before using it as a source.","operator_label":"Short text","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"partial_text","label":"Partial text","has_full_text":true,"has_summary":true,"content_length":188,"summary_length":188,"usable_text_length":188,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":188,"summary_length":188}}},"quality_profile":{"profile_version":"extraction_quality.v2","bucket":"medium","confidence":0.75,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"Medium confidence: short full text extraction produced 188 characters.","operator_guidance":{"severity":"info","recommended_action":"review_short_text","next_step":"Review the short extracted text before using it as a source.","operator_label":"Short text","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"partial_text","label":"Partial text","has_full_text":true,"has_summary":true,"content_length":188,"summary_length":188,"usable_text_length":188,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":188,"summary_length":188}},"actions":{"read":"/item/89964","export_markdown":"/api/items/89964/export?format=markdown","export_json":"/api/items/89964/export?format=json","diagnose":"/api/diagnose?url=https%3A//www.sohu.com/a/1052284719_121157270"}},"digest":{"id":89964,"title":"三星生物收购PolyPeptide，打通多肽原料药赛道 - 搜狐网","url":"https://www.sohu.com/a/1052284719_121157270","source":"搜狐网","topic":"peptides","published_at":"2026-07-20T07:00:00+00:00","excerpt":"7月20日，三星生物（Samsung Biologics）7月20日宣布，拟通过现金要约收购瑞士多肽药物原料药合同开发与生产企业PolyPeptide Group AG全部已发行股份，报价为每股44.31瑞郎，交易股权价值约14.6亿瑞郎。 三星生物表示，此次收购将推动公司从抗体和抗体偶联药物（ADC）领域进一步拓展至多肽疗法，强化多模态CDMO（合同开发与生产组织）平台。","quality_bucket":"medium","quality_reason":"Medium confidence: short full text extraction produced 188 characters.","reading_time_min":1,"cluster_id":null},"card":{"display_title":"三星生物收购PolyPeptide，打通多肽原料药赛道 - 搜狐网","subtitle":"搜狐网 · 2026-07-20","summary":"7月20日，三星生物（Samsung Biologics）7月20日宣布，拟通过现金要约收购瑞士多肽药物原料药合同开发与生产企业PolyPeptide Group AG全部已发行股份，报价为每股44.31瑞郎，交易股权价值约14.6亿瑞郎。 三星生物表示，此次收购将推动公司从抗体和抗体偶联药物（ADC）领域进一步拓展至多肽疗法，强化多模态CDMO（合同开发与生产组织）平台。","badges":["quality:medium"],"links":{"read":"/item/89964","original":"https://www.sohu.com/a/1052284719_121157270","diagnose":"/api/diagnose?url=https%3A//www.sohu.com/a/1052284719_121157270"},"quality_warning":null},"export":{"title":"三星生物收购PolyPeptide，打通多肽原料药赛道 - 搜狐网","url":"https://www.sohu.com/a/1052284719_121157270","summary":"7月20日，三星生物（Samsung Biologics）7月20日宣布，拟通过现金要约收购瑞士多肽药物原料药合同开发与生产企业PolyPeptide Group AG全部已发行股份，报价为每股44.31瑞郎，交易股权价值约14.6亿瑞郎。\n三星生物表示，此次收购将推动公司从抗体和抗体偶联药物（ADC）领域进一步拓展至多肽疗法，强化多模态CDMO（合同开发与生产组织）平台。","source":"搜狐网","date":"2026-07-20T07:00:00+00:00","content":"7月20日，三星生物（Samsung Biologics）7月20日宣布，拟通过现金要约收购瑞士多肽药物原料药合同开发与生产企业PolyPeptide Group AG全部已发行股份，报价为每股44.31瑞郎，交易股权价值约14.6亿瑞郎。\n三星生物表示，此次收购将推动公司从抗体和抗体偶联药物（ADC）领域进一步拓展至多肽疗法，强化多模态CDMO（合同开发与生产组织）平台。","confidence":0.75,"diagnostics_url":"/api/diagnose?url=https%3A//www.sohu.com/a/1052284719_121157270","quality_bucket":"medium","failure_kind":"none","retryable":false,"quality_reason":"Medium confidence: short full text extraction produced 188 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"medium","confidence":0.75,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"Medium confidence: short full text extraction produced 188 characters.","operator_guidance":{"severity":"info","recommended_action":"review_short_text","next_step":"Review the short extracted text before using it as a source.","operator_label":"Short text","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"partial_text","label":"Partial text","has_full_text":true,"has_summary":true,"content_length":188,"summary_length":188,"usable_text_length":188,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":188,"summary_length":188}},"tags":[],"format_contract_version":"news_item_formats.v1"}}}